Testosterone-boosting Medications and Cardiovascular Risk

- a systematic review and meta-analysis

Testosterone-boosting Medications and Cardiovascular Risk

Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Corona G, Maseroli E, Rastrelli G, et al. Expert opinion on drug safety. Oct 2014;13(10):1327-1351.

Accumulating evidence shows beneficial effects of testosterone therapy on a wide range of health outcomes, including inflammation, insulin sensitivity, muscle mass, body fat mass, lipid profiles, endothelial (blood vessel) function, bone mineral density, energy and vitality, mood, sexual function and overall quality of life.1-9 Despite this, concerns have been raised that testosterone therapy could have detrimental effects on cardiovascular disease.

This editorial summarizes results from a comprehensive systematic review and meta-analysis, the largest to date, of all placebo-controlled randomized clinical trials (RCTs) on the effect of testosterone therapy on cardiovascular-related problems.10

KEY POINTS10

  • This analysis, performed on the largest number of studies collected so far, indicates that testosterone therapy is not related to any increase in cardiovascular risk.
  • Present data do not support a causal role between testosterone therapy and cardiovascular events.
  • In studies performed in subjects with metabolic derangements a protective effect of testosterone therapy on cardiovascular risk was observed.
  • Testosterone therapy in hypogonadal men can be a valuable strategy to improve metabolic profile, reduce body fat and increase lean muscle mass, which would ultimately reduce the risk of heart disease.
  • No sponsorship bias was detected, because no difference in MACE risk was found when the analysis was performed according to the presence or absence of drug company financing.
  • This new systematic review and meta-analysis of randomized controlled trials reporting the effects of testosterone therapy on different cardiovascular outcomes, included 75 RCTs with a total of 3016 patients on testosterone therapy and 2448 patients on placebo, for mean duration of 34 weeks.
  • The principal outcome of this analysis was the effect of testosterone therapy, as compared with placebo, on the incidence of new major adverse cardiovascular events (MACE). MACE was defined as the composite of cardiovascular death, non-fatal acute myocardial infarction and stroke, and acute coronary syndromes and/or heart failure reported as serious adverse events. This was done to comply with requirements for drug safety assessment, as required by regulatory agencies.
  • The mean age, baseline testosterone level and body mass index (BMI) of enrolled patients were 59.9 years, 11.2 nmol/L (323 ng/dL) and 28.1 kg/m2.
  • Testosterone was administered in different doses, formulations (oral, intramuscular and transdermal testosterone preparations) and in mixed populations of hypogonadal/eugonadal subjects.

What is known

The notion that testosterone is "bad for the heart" arose from the well documented simple observation that heart diseases are more prevalent in men than in women.11-18 Acute coronary heart disease and ischaemic stroke events appears approximately 10 years earlier in men than in women, and these rates remain higher in men than in women in all age groups.11 More men are living with and dying of coronary heart disease than women, and have more hospital discharges for cardiovascular diseases.19 These observations contributed to the perception that heart disease is a “man’s disease”.19

Because men have higher testosterone, it was automatically assumed that testosterone may be the culprit. Further support for this notion comes from case reports of sudden cardiovascular death amongst male athletes abusing anabolic steroids (which are synthetic compounds similar to testosterone)20-24, and observations that testosterone dose-dependently increases hematocrit25,26 and reduces HDL-cholesterol at supra-physiologically high levels.27-29

However, longitudinal studies which follow large populations of men for many years demonstrate that it is reduced, rather than increased testosterone levels, which are associated with elevated risk of cardiovascular disease, cardiovascular mortality and all-cause mortality.30,31 This can be explained by the well documented strong associations of hypogonadism with a number of cardiovascular risk factors, including adiposity and increased waist circumference, insulin resistance and type 2 diabetes, high blood pressure and inflammation.32-37

What this study adds

The results from the comprehensive systematic review and meta-analysis presented here show that testosterone therapy is not related to any increase in cardiovascular risk, and that it may have a protective effect on cardiovascular risk in men with metabolic derangements.10 This conclusion is based on an analysis of the largest number of studies collected so far, which clearly refutes the previously purported causal role between testosterone therapy and cardiovascular events.

A strength of this meta-analysis is that its principal outcome was the effect of testosterone therapy, as compared with placebo, on the incidence of new major adverse cardiovascular events (MACE).10 A previous meta-analysis, which concluded that testosterone therapy increased the risk of cardiovascular-related events38, included many events which are not typically considered for the assessment of cardiovascular risk (e.g., peripheral edema, self-reported syncope etc.). This can be grossly misleading due to the limited reliability of diagnostic criteria used to attribute these events as drug-related. It should be recognized that the use of MACE, instead of a broader ambiguous definition of cardiovascular side effects, has the advantage of a clearer diagnostic definition and precise diagnosis, which is less dependent on investigators’ subjective opinions. Therefore, the assessments of cardiovascular safety of any therapy should be based on the incidence of MACE, which are easier to detect and less controversial in diagnosis. It should be underscored that regulatory agencies assessing the safety of drugs require analyses of MACE and not of broadly defined cardiovascular side effects.39

This meta-analysis also did not observe any sponsorship bias, because no difference in cardiovascular risk was found when the analysis was performed according to the presence or absence of drug company funding.10 This is also in contrast to the meta-analysis just mentioned, which reported that the effects of testosterone on cardiovascular-related events varied with source of funding.38

Supporting data from other studies

Multiple other lines of evidence concur with the conclusions in this meta-analysis. Two notable studies demonstrated that testosterone therapy decreases mortality compared with no testosterone treatment40, and improves survival in hypogonadal men with type 2 diabetes.41 Further support comes from The MrOS (Osteoporotic Fractures in Men) study which after a 5-year follow-up found that an apparent threshold of over 550 ng/dL (approximately 19 nmol/L) needs to be reached in order to reduce risk of cardiovascular events.42 In this study, men in the group with highest testosterone level over 550 ng/dL had a 30% lower risk of cardiovascular events compared with men with testosterone levels below 550 ng/dL, where no protective effect was noted.42 This association remained after adjustment for traditional cardiovascular risk factors and was not changed in analyses excluding men with known cardiovascular disease at.42

Reflections

A few flawed studies of epidemiological observations induced an epidemic of sensational and misleading media coverage and false claims alleging potential dangerous effect of testosterone therapy on the cardiovascular system.43,44 Over the past year popular press headlines have purported that testosterone therapy is associated with serious cardiac hazards. However, as outlined here, meta-analysis of the largest number of studies collected to date shows that testosterone therapy does not increase cardiovascular events, and to the contrary, that it is protective against cardiovascular events in hypogonadal men.10

According to expert opinion, testosterone therapy in hypogonadal men can be a valuable strategy to improve metabolic profile, reduce body fat and increase lean muscle mass, which would ultimately reduce the risk of heart disease.10

References

1. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. 2014;83(1):167-173.
2. Haider A, Meergans U, Traish A, et al. Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. International journal of endocrinology. 2014;2014:496948.
3. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract. 2014;8(4):e339-349.
4. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International journal of endocrinology. 2014;2014:683515.
5. Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from Five Year-median Follow-up of Three Registries. J. Urol. 2014.
6. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013;21(10):1975-1981.
7. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 2014;68(3):314-329.
8. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical obesity. 2013;3(3-4):73-83.
9. Traish AM. Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids. 2014;88C:117-126.
10. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert opinion on drug safety. 2014;13(10):1327-1351.
11. Hyvarinen M, Qiao Q, Tuomilehto J, Soderberg S, Eliasson M, Stehouwer CD. The difference between acute coronary heart disease and ischaemic stroke risk with regard to gender and age in Finnish and Swedish populations. International journal of stroke : official journal of the International Stroke Society. 2010;5(3):152-156.
12. Mikkola TS, Gissler M, Merikukka M, Tuomikoski P, Ylikorkala O. Sex differences in age-related cardiovascular mortality. PloS one. 2013;8(5):e63347.
13. Ng MK. New perspectives on Mars and Venus: unravelling the role of androgens in gender differences in cardiovascular biology and disease. Heart, lung & circulation. 2007;16(3):185-192.
14. Perez-Lopez FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci. 2010;17(6):511-531.
15. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J. Clin. Endocrinol. Metab. 2005;90(5):2708-2711.
16. Rosano GM. Androgens and coronary artery disease. A sex-specific effect of sex hormones? Eur. Heart J. 2000;21(11):868-871.
17. Seifarth JE, McGowan CL, Milne KJ. Sex and life expectancy. Gender medicine. 2012;9(6):390-401.
18. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nature reviews. Cardiology. 2009;6(8):532-542.
19. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124(19):2145-2154.
20. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90(5):473-475.
21. Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur. Heart J. 1996;17(10):1576-1583.
22. Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation. Heart failure. 2010;3(4):472-476.
23. Kersey RD, Elliot DL, Goldberg L, et al. National Athletic Trainers' Association position statement: anabolic-androgenic steroids. Journal of athletic training. 2012;47(5):567-588.
24. Rothman RD, Weiner RB, Pope H, et al. Anabolic androgenic steroid induced myocardial toxicity: an evolving problem in an ageing population. BMJ case reports. 2011;2011.
25. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J. Clin. Endocrinol. Metab. 2008;93(3):914-919.
26. Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb. Haemost. 1995;74(2):693-697.
27. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-1181.
28. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J. Clin. Endocrinol. Metab. 2002;87(1):136-143.
29. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J. Clin. Endocrinol. Metab. 2005;90(2):678-688.
30. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur. J. Endocrinol. 2011;165(5):687-701.
31. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2011;96(10):3007-3019.
32. Traish AM. Adverse health effects of testosterone deficiency (TD) in men. Steroids. 2014;88C:106-116.
33. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am. J. Med. 2011;124(7):578-587.
34. Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm. Metab. Res. 2011;43(3):153-164.
35. Tsujimura A. The Relationship between Testosterone Deficiency and Men's Health. The world journal of men's health. 2013;31(2):126-135.
36. Maggio M, Basaria S. Welcoming low testosterone as a cardiovascular risk factor. Int. J. Impot. Res. 2009;21(4):261-264.
37. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? Int. J. Impot. Res. 2009;21(1):24-36.
38. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC medicine. 2013;11:108.
39. U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov Accessed Sept 29, 2014.
40. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J. Clin. Endocrinol. Metab. 2012;97(6):2050-2058.
41. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol. 2013;169(6):725-733.
42. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J. Am. Coll. Cardiol. 2011;58(16):1674-1681.
43. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS one. 2014;9(1):e85805.
44. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
Last updated: 2017
G.GM.MH.04.2015.0334